Introduction
============

Pancreatic and bile duct cancers remain devastating diagnoses with 5-year survival rates of only 8 % to 10 % [@OR1699-1] [@OR1699-2] . These malignancies are generally diagnosed at a later stage and for this reason, surgery as initial management is a consideration in only a small minority of cases. Optimal treatment of locally advanced pancreatobiliary malignancies is evolving rapidly and the role of chemotherapy alone vs. chemoradiation is the topic of ongoing investigation [@JR1699-3] [@JR1699-4] , with many centers offering chemoradiation as the first-line option.

Stereotactic body radiation therapy (SBRT) is increasingly being used as an alternative to conventional radiation therapy. This is because of the potential of SBRT to provide a higher combined dose of radiation over fewer treatments for pancreaticobiliary cancers and other malignancies [@JR1699-5] [@JR1699-6] . SBRT requires highly precise targeting of the tumor tissue and for this reason, many SBRT protocols require the placement of fiducial markers in or near the tumor.

Fiducials have been proven to be better surrogate markers for tumor position than stents or other anatomical landmarks [@JR1699-7] . Fiducial markers were originally placed intraoperatively or percutaneously under radiologic guidance [@JR1699-8] [@JR1699-9] [@JR1699-10] . Endoscopic ultrasound has now assumed a dominant role for fiducial placement due to its close proximity to pancreatobiliary structures, offering improved access to pancreaticobiliary anatomy and other GI structures [@JR1699-11] [@JR1699-12] [@JR1699-13] . Data on safety and efficacy, however, still remain fairly limited. In addition, use of antibiotics during EUS-guided fiducial placement varies in clinical practice and the benefit remains unknown. The goal of the current study was to assess the safety and efficacy of EUS-guided fiducial placement in a large single-center series, as well as to assess risk of infection in patients undergoing fiducial placement with and without peri-procedural antibiotics.

Patients and methods
====================

We performed a retrospective, single-center study of consecutive patients who underwent EUS-guided fiducial placement by three expert interventional endoscopists from July 2010 to February 2018 at a tertiary care hospital. All patients underwent EUS with linear echoendoscope (Olympus Corporation, Center Valley, Pennsylvania, United States). Based on availability and endoscopist preference, either a 19-gauge (Wilson Cook Medical, Winston-Salem, North Carolina, United States; Beacon Endoscopy/Medtronic Inc, Sunnyvale, California, United States) fine-needle aspiration (FNA) needle loaded with 0.8 × 3-mm gold fiducial or a preloaded 22-gauge fiducial needle (Beacon Endoscopy/Medtronic Inc, Sunnyvale, California, United States) with 0.43 × 5-mm gold fiducial were used for placement. For the standard 19 g FNA needle, one fiducial was loaded at a time, with bone wax to fix the fiducial in place prior to deployment, and a new fiducial had to be loaded after each needle pass. The dedicated 22-gauge fiducial needle is pre-loaded with two fiducials, and a second pre-loaded needle was used for placement of additional fiducials. Standard EUS approaches using Doppler guidance were used to place fiducials in and around the target tissue, with the goal of placing more than two fiducials when feasible. The decision to use prophylactic antibiotics was at the discretion of the endoscopist.

Patient demographics, EUS technical details, tumor characteristics, co-morbidities, prophylactic antibiotic use, adverse events (AEs) and administration of SBRT/Cyberknife were recorded. The pattern of prophylactic antibiotic use was categorized as pre-procedural (IV single dose), post-procedural (oral, for 3--7 days), or both.

AEs were categorized as mild, moderate and severe based on the American Society for Gastrointestinal Endoscopy (ASGE) lexicon for endoscopy events [@JR1699-14] . Moderate and severe AEs included major bleeding requiring blood transfusion, cholangitis, bacteremia (positive blood cultures), pancreatitis and septic shock. Mild AEs included pain, fever, transaminitis (ALT and/or AST \> 3 × upper limit of normal) and minor bleeding not requiring transfusion.

Analysis was performed using SPSS software. Chi-square test was used to test for statistical significance and a two tailed *P*  \< 0.05 was considered statistically significant. Test of Pearson Correlation was used with the correlation coefficient comprised between --1 and 1 where --1 indicates strong negative correlation, 1 indicates strong positive correlation and 0 indicates no association between the two variables. The study was approved by the local Institutional Review Board.

Results
=======

A total of 355 patients underwent EUS-guided fiducial placement, with an age range between 34 and 92 years (mean age 68.5 years). Of them, 181 patients (51 %) were male and 174 (49 %) were female. The most common diagnosis was pancreatic adenocarcinoma (n = 299, 84.2 %) followed by cholangiocarcinoma (n = 16), renal cell carcinoma with pancreatic metastases (n = 10), and hepatocellular carcinoma (n = 7) ( [Table 1](#TB1699-1){ref-type="table"} ). The majority of tumors were located in the head of the pancreas (n = 207, 58.3 %).

###### Patient characteristics and indication of fiducial placement.

                                                                                                      N (%)
  ----------------------------------------------------------------------- --------------------------- -----------------------
  Gender                                                                  Males                       181 (51 %)
  Females                                                                 174 (49 %)                  
  Age                                                                     Mean                         68.5 (34-- 92 years)
  Cancer                                                                  Pancreatic adenocarcinoma   298
  Cholangiocarcinoma                                                       16                         
  RCC with pancreatic metastases                                           10                         
  Hepatocellular carcinoma                                                  7                         
  Pancreatic neuroendocrine tumor                                           5                         
  Esophageal carcinoma                                                      4                         
  Gall bladder carcinoma                                                    3                         
  Ampullary carcinoma                                                       3                         
  Stomach adenocarcinoma                                                    2                         
  Metastatic melanoma with peripancreatic mass at portal confluence         1                         
  Intraductal papillary mucinous Neoplasm with malignant transformation     2                         
  SCC metastases in head of pancreas                                        1                         
  Prostate cancer with metastases in head of pancreas                       1                         
  Ovarian cancer with metastases in head of pancreas                        1                         
  Colon cancer with liver metastases                                        1                         
  Tumor consistency                                                       Solid                       343
  Cystic                                                                    3                         
  Mixed                                                                     9                         
  Tumor size                                                              Average size                  2.86 cm
                                                                          Ill-defined masses (n)       49

RCC, renal cell carcinoma; SCC, squamous cell carcinoma.

A total of 1186 fiducials were placed with a range of one to four fiducials per patient (mean of 3.33). Fiducials were placed using a 19-gauge FNA needle in 61 % patients (n = 211) and with a preloaded 22-gauge fiducial needle in 39 % patients (n = 136). Of the 355 patients, 304 (85.63 %) received prophylactic antibiotic and 51 (14.37 %) did not. Among patients who received antibiotics, 107 received only pre-procedural antibiotic, 32 received only post-procedure antibiotics, and 165 received antibiotics both pre- and post-procedure.

Of the total 355 patients, 308 (86.76 %) patients underwent SBRT successfully. Eighteen patients were lost to follow-up or transitioned to other facilities, 17 patients had interval disease progression, seven died before SBRT, three declined treatment, and one patient had an initial diagnosis of malignancy changed to a benign diagnosis. One patient could not undergo SBRT due to inability of the Cyberknife system to track the fiducials. This patient underwent an initial SBRT session 13 days after four fiducial markers were placed at the borders of a 3.9-cm pancreatic head adenocarcinoma. The SBRT session was aborted after 10 % of targeted treatment. Review of the patient's inspiration/expiration scans revealed significant torsional motion of the target with breathing. In addition, the fiducials were noted to be located at the top of the target volume in a cluster, making tracking less reliable.

Twenty-one of 355 patients (5.9 %) developed procedural AEs ( [Table 2](#TB1699-2){ref-type="table"} ). Three patients developed acute pancreatitis, although two of them had undergone same-session ERCP. One patient had major bleeding requiring blood transfusion after EUS-guided fiducial placement. One of 51 patients (2 %) with no antibiotic use developed acute cholangitis, whereas two of 304 (0.7 %) with prophylactic antibiotic use developed bacteremia and septic shock respectively. Importantly, only one patient had a definitive biliary source (cholangitis likely secondary to biliary stent displacement), while the other two patients had other likely sources of sepsis including pneumonia and *Clostridium difficile* . In any case, occurrence of moderate to severe infectious AEs (bacteremia, acute cholangitis and septic shock) was rare and not statistically significantly different between the two groups, nor was post-procedure fever, with or without use of peri-procedural antibiotics ( [Table 3](#TB1699-3){ref-type="table"} and [Table 4](#TB1699-4){ref-type="table"} ).

###### Characteristics of fiducial placement, concurrent bile stent, chemotherapy and antibiotic use.

                                                                                               N (%)
  -------------------------------- ----------------------------------------------------------- ---------------------------------------------
  Fiducials                        Total number placed                                         1186
                                   Average no. per patient                                        3.33 (1--4; only 1 patient had 6 placed)
  Needle type                      19 g                                                         211 (60.8 %)
                                   22 g                                                         136 (39.2 %)
  Location of fiducial placement   Pancreatic head                                              207 (58.3 %)
                                   Body                                                          56 (15.8 %)
                                   Neck                                                          21 (5.9 %)
                                   Uncinate process                                              15 (4.2 %)
                                   Tail                                                           9 (2.5 %)
                                   Porta hepatis                                                  8 (2.3 %)
                                   Common bile duct mass                                          5 (1.4 %)
                                   Gastro-hepatic lymph nodes                                     4
                                   Pancreatic tumor bed s/p Whipple's                             3
                                   Liver                                                          3
                                   Para-esophageal lymph nodes                                    3
                                   Gall bladder                                                   3
                                   Celiac lymph nodes                                             2
                                   Head, neck and body                                            2
                                   Body and tail                                                  1
                                   Neck and uncinate process                                      1
                                   Others                                                        12 (3.4 %)
  Presence of bile duct stents     Yes                                                          167 (47 %)
                                   No stents                                                    188 (53 %)
  Antibiotic pattern               Pre- and post-procedure                                      165 (46.5 %)
                                   Pre-procedure                                                107 (30.1 %)
                                   Post-procedure                                                32 (9.1 %)
                                   No antibiotics                                                51 (14.4 %)
  Endoscopists                     Attending 1                                                  111 (31.3 %)
                                   Attending 2                                                  163 (45.9 %)
                                   Attending 3                                                   81 (22.8 %)
  Cyber-knife therapy              Yes                                                          308 (86.76 %)
                                   No                                                            47 (13.24 %)
  Chemotherapy                     Within 2 weeks before or after procedure                     176 (49.6 %)
                                   No chemotherapy                                              179 (50.4 %)
  Adverse Events (AEs)             Present                                                       21 (5.9 %)
                                   Absent                                                       334 (94.1 %)
                                   Infectious AEs (excluding fever with no confirmed source)      3/355 (0.84 %)

###### Characteristics of patients with adverse events after fiducial placement.

       Age/Sex   Tumor                                Type     Concurrent ERCP or FNA or CPN   Bile duct stent   No. of fiducials placed   Needle   Antibiotic                                 Chemotherapy             CyberKnife Radiation   Adverse events
  ---- --------- ------------------------------------ -------- ------------------------------- ----------------- ------------------------- -------- ------------------------------------------ ------------------------ ---------------------- -----------------------------------------------------
   1   62/M      Pancreatic Ca                        Solid    ERCP                            FCSEMS            4                         19 g     PO Ciprofloxacin                           Gemcitabine              Yes                    Pain requiring hospitalization
   2   65/M      Pancreatic Ca                        Solid    ERCP                            FCSEMS            4                         19 g     IV Ciprofloxacin + PO Augmentin            --                       No                     Transaminitis, Major bleeding requiring transfusion
   3   60/F      CholangioCa                          Solid    --                              FCSEMS            2                         19 g     IV Ciprofloxacin                           Gemcitabine, Cisplatin   Yes                    Pain
   4   79/F      CholangioCa                          Solid    --                              FCSEMS            3                         19 g     --                                         --                       Yes                    Pain requiring hospitalization
   5   77/F      Ampullary Ca                         Solid    --                              SEPS              3                         19 g     --                                         --                       Yes                    Acute Cholangitis
   6   69/M      CholangioCa                          Solid    --                              FCSEMS            3                         19 g     IV Ciprofloxacin                           Gemcitabine, Cisplatin   Yes                    C. difficile colitis, Bacteremia
   7   67/M      Pancreatic Ca                        Solid    ERCP                            FCSEMS            3                         19 g     IV Ampicillin + IV Flagyl + PO Augmentin   --                       Yes                    Pancreatitis
   8   63/F      Pancreatic Ca                        Solid    ERCP, FNA, CPN                  FCSEMS            3                         19 g     IV + PO Ciprofloxacin                      Gemcitabine              Yes                    Pain
   9   89/M      IPMN with malignant transformation   Cystic   ERCP, FNA                       FCSEMS            4                         19 g     IV + PO Ciprofloxacin                      --                       No                     Septic shock
  10   71/M      Pancreatic Ca                        Solid    --                              No stent          3                         19 g     IV + PO Ciprofloxacin                      Folfirinox               Yes                    Minor bleeding
  11   83/F      Pancreatic Ca                        Mixed    CPN                             FCSEMS            3                         19 g     IV Ciprofloxacin                           Gemcitabine              Yes                    Fever, Pain
  12   34/F      CholangioCa                          Solid    --                              UCSEMS            2                         19 g     IV Ciprofloxacin                           Gemcitabine, Cisplatin   Yes                    Fever, Pain requiring hospitalization
  13   45/F      Pancreatic NET                       Solid    ERCP                            UCSEMS            4                         19 g     IV + PO Ciprofloxacin                      --                       Yes                    Pancreatitis
  14   78/M      Pancreatic Ca                        Solid    ERCP                            FCSEMS            3                         19 g     IV Ciprofloxacin                           --                       Yes                    Pain requiring hospitalization
  15   59/F      Pancreatic Ca                        Solid    --                              No stent          4                         22 g     IV Imipenem                                --                       Yes                    Pancreatitis
  16   75/F      Pancreatic Ca                        Solid    --                              FCSEMS            4                         22 g     IV + PO Ciprofloxacin                      Gemcitabine              Yes                    Pain requiring hospitalization
  17   68/M      CholangioCa                          Solid    --                              No stent          3                         19 g     IV + PO Ciprofloxacin                      Gemcitabine, Cisplatin   Yes                    Fever, Pain requiring hospitalization
  18   67/M      Pancreatic Ca                        Solid    FNA                             FCSEMS            3                         19 g     IV + PO Ciprofloxacin                      --                       Yes                    Pain, minor bleeding
  19   66/M      Pancreatic Ca                        Solid    --                              No stent          4                         19 g     IV Ciprofloxacin                           Folfirinox               Yes                    Fever requiring hospitalization
  20   64/F      Pancreatic Ca                        Solid    --                              No stent          4                         22 g     IV Ciprofloxacin + PO Augmentin            Folfirinox               Yes                    Fever
  21   73/M      Pancreatic Ca                        Solid    --                              No stent          4                         22 g     IV Ciprofloxacin                           --                       Yes                    Pain

NET, neuro-endocrine tumor; Ca, carcinoma; IPMN, intraductal papillary mucinous neoplasm; ERCP, endoscopic retrograde cholangiopancreatography; FNA, fine-needle aspiration; CPN, celiac plexus neurolysis; FCSEMS, fully-covered self-expanding metal stent; UCSEMS, uncovered self-expanding metal stent; SEPS, self-expanding plastic stent.

###### Statistical significance of use of prophylactic antibiotics and infectious adverse events.

                     Antibiotic used   No antibiotic used   *P* value (significant \< 0.05)
  ------------------ ----------------- -------------------- ---------------------------------
  Major Infections   1/51              2/304                0.35
  Fever              2/51              6/304                0.32

There was no significant correlation between infection risk and type of tumor (solid, cystic or mixed) (r = 0.12), location of tumor (r = 0.124), type of needle used (r = -.036) or recent chemotherapy (r = 0.029). Additionally, number of fiducials placed (1--6) and needle gauge (19-g vs. 22-g) did not correlate with risk of mild or moderate-severe AEs.

Discussion
==========

Our study demonstrates that EUS-guided fiducial placement is safe and feasible for pancreaticobiliary malignancy. AEs, including infectious AEs, are exceedingly rare. To our knowledge, this is the largest study to date evaluating the safety and efficacy of EUS-guided fiducial placement for pancreatobiliary and associated malignancies.

Despite the large sample size, the benefit of prophylactic antibiotics was not significant statistically and perhaps would require an even larger study population and a randomized design to illustrate. We did not find any significant correlation between infectious AEs and tumor type, location, type of needle used or recent chemotherapy. It is worth also carefully considering the patients in whom infection did develop, as only one of three had a definitive biliary source. In the one patient who developed cholangitis (without prophylactic antibiotics during fiducial placement), the patient had a diagnosis of ampullary cancer, with a plastic biliary stent in place prior to EUS. The patient presented with cholangitis several days after fiducial placement and was found to have displacement of the previously placed plastic stent. Given that the fiducials were placed in the vicinity of the stent, it is possible that fiducial placement may have inadvertently contributed to stent displacement and/or contributed directly to bacterial seeding of the bile duct. One patient who presented with sepsis and did receive prophylactic pre- and post-procedure antibiotic had undergone same session ERCP with stent exchange, along with EUS-guided fiducial placement. This patient was readmitted 2 days later with septic shock, slightly elevated bilirubin levels, and evidence of pneumonia, and was transitioned to comfort care before additional diagnostic steps could be taken. The third patient with a potentially-related infection had received a single pre-procedural dose of intravenous antibiotics before fiducial placement and was hospitalized 10 days after EUS with fever and *Escherichia coli* bacteremia and was diagnosed with concurrent *C. difficile* .

On review of literature, we identified only three reports of infectious AEs (cholangitis) with EUS-guided fiducial placement for intra-abdominal malignancies, and all were in patients who had not received peri-procedural antibiotics [@JR1699-15] [@JR1699-16] [@JR1699-17] . In the available studies published in which patients received prophylactic antibiotics [@JR1699-9] [@JR1699-12] [@JR1699-13] [@JR1699-16] [@JR1699-17] [@JR1699-18] [@JR1699-19] [@JR1699-20] [@JR1699-21] [@JR1699-22] [@JR1699-23] [@JR1699-24] ( [Table 5](#TB1699-5){ref-type="table"} ), no infectious AEs were reported in our review.

###### Safety and efficacy of EUS-guided fiducial placement in pancreatobiliary malignancies.

  Study                                    Type of study   Number of pancreatobiliary cases            Prophylactic antibiotic use N (%)   Technical success N (%)   Adverse events (n)
  ---------------------------------------- --------------- ------------------------------------------- ----------------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Pishvaian et al (2006) [@JR1699-16]      Prospective      13                                           5 (38.5 %)                         11 (85 %)                Cholangitis (1)
  Kothary et al (2009) [@JR1699-9]         Retrospective    95                                         Not reported                         94 (97.9 %)              Minor bleeding (3), fiducial migration (2)
  Varadarajulu et al (2010) [@JR1699-19]   Retrospective     9                                         None                                  9 (100 %)               None
  Park et al (2010) [@JR1699-20]           Prospective      57                                          57 (100 %)                          56 (98 %)                Minor bleeding (1)
  Sanders et al (2010) [@JR1699-12]        Prospective      51                                          51 (100 %)                          46 (90 %)                Mild pancreatitis (1)
  Ammar et al (2010) [@JR1699-21]          Case Series      13                                          13 (100 %)                          13 (100 %)               None
  Khashab et al (2012) [@JR1699-22]        Retrospective    39                                          39 (100 %)                          39 (100 %)               None
  Dimaio et al (2010) [@JR1699-17]         Retrospective    10 (remaining 20 cases  were esophageal)     6 (out of total  30 cases)         10 (100 %)               Fever with transaminitis (1) (No prophylactic antibiotic)
  Majumdar et al (2013) [@JR1699-13]       Retrospective    39 (out of total 77)                        39 (100 %)                          39 (100 %)               Pain (3), mild pancreatitis (1), fiducial migration (4)
  Choi et al (2014) [@JR1699-23]           Retrospective    32                                          32 (100 %)                          32 (100 %)               Mild pancreatitis (1)
  Dhadham et al (2016) [@JR1699-18]        Retrospective   188                                         Not reported                        187 (99.5 %)              Minor bleeding (7), fiducial migration (3)
  Machicado et al (2019) [@JR1699-24]      Prospective      44                                         Not reported                         42 (95.5 %)              Pain (19), Nausea and/or vomiting (9)
  Current study                            Retrospective   355                                         304 (85.6 %)                        355 (100 %)               Pain (7), fever (5), minor (2) and major bleeding (1), pancreatitis (3), cholangitis (1), Bacteremia (1), septic shock (1)

EUS, endoscopic ultrasound

There are no clear guidelines on use of antibiotic prophylaxis in EUS-guided fiducial placement. The American Society of Gastrointestinal Endoscopy recommends against antibiotic prophylaxis before diagnostic EUS or EUS-FNA of solid lesions of the gastrointestinal tract and suggests their use before diagnostic FNA of cystic lesions [@JR1699-25] . Results of the current study, along with the prior smaller studies referenced above, suggest that infection after fiducial placement is exceedingly rare. In our own large study, there was only one definitive biliary infection (likely due to stent displacement) in a patient who had not received prophylactic antibiotics, and two patients with several possible infections including, respectively, pneumonia and *C. difficile* , who both received antibiotics.

The major limitations of our study include the retrospective nature of data collection, selective and non-randomized use of antibiotics, and low rate of AEs, including infectious. It is possible that our study was underpowered to detect important risk factors for infection and other AEs after EUS-guided fiducial placement. However, this study accounts for the largest number of patients undergoing EUS-guided fiducial placement for pancreatobiliary malignancies to date. There was 100 % clinical success in fiducial placement with a low rate of mild to severe AEs and no significant difference in occurrence of infectious AEs, with or without use of prophylactic antibiotics. It is our opinion that fiducial placement in or near a cystic mass, and fiducial placement in or near a biliary stricture which may not be adequately drained, are both scenarios where infection risk could be reasonably judged to be higher, and for which prophylactic antibiotic use could be favored on an individual basis. This selective approach derives more from guidelines and experience on the management of cystic lesions and bile duct interventions, rather than strong evidence in our study or any prior data on fiducial placement specifically.

Conclusion
==========

EUS-guided fiducial placement for pancreatobiliary malignancy is safe and efficacious, and risk of infection is rare, regardless of whether or not peri-procedural antibiotics are used. For most patients, we recommend against routine use of antibiotics for EUS-guided fiducial placement for three reasons: 1) infectious AEs are exceedingly rare in this setting; 2) there are no data to suggest that routine use of antibiotics meaningfully reduces risk of these events; and 3) routine antibiotic use may expose patients to medication-related AEs and contribute to antibiotic resistance.
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